Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Genomics & Proteomics
  • Other Publications
    • Cancer Genomics & Proteomics
    • Anticancer Research
    • In Vivo
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Cancer Genomics & Proteomics

Advanced Search

  • Home
  • Content
    • Current
    • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • In Vivo
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review ArticleArticles

Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer

TAKASHI HIGUCHI, QINGHONG HAN, NORIHIKO SUGISAWA, JUN YAMAMOTO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, MICHAEL BOUVET, SHREE RAM SINGH, HIROYUKI TSUCHIYA and ROBERT M. HOFFMAN
Cancer Genomics & Proteomics March 2021, 18 (2) 113-120; DOI: https://doi.org/10.21873/cgp.20246
TAKASHI HIGUCHI
1AntiCancer, Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
QINGHONG HAN
1AntiCancer, Inc., San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIHIKO SUGISAWA
1AntiCancer, Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUN YAMAMOTO
1AntiCancer, Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORIO YAMAMOTO
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUHIRO HAYASHI
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROAKI KIMURA
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHINJI MIWA
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KENTARO IGARASHI
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MICHAEL BOUVET
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHREE RAM SINGH
4Basic Research Laboratory, National Cancer Institute, Frederick, MD, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp
HIROYUKI TSUCHIYA
3Department of Orthopedic Surgery, Kanazawa University, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp
ROBERT M. HOFFMAN
1AntiCancer, Inc., San Diego, CA, U.S.A.;
2Department of Surgery, University of California, San Diego, CA, U.S.A.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: all@anticancer.com singhshr@mail.nih.gov tsuchi@med.kanazawa-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Treatment schema. DOX: Doxorubicin; o-rMETase: oral recombinant methioninase; DAC: decitabine.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    (A) Relative tumor volume of the USTS-PDOX model. (B)Waterfall plot of relative tumor volume. Six mice were in each group. *p=0.05; **p=0.01; ***p=0.001. Error bars: ±SEM. USTS, Undifferentiated/unclassified soft-tissue sarcoma; PDOX, patient-derived orthotopic xenograft; o-rMETase, oral recombinant methioninase; CL, cycloleucine; DOX, doxorubicin; DAC, decitabine; SEM, standard error of the mean.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    (A) Representative photographs of treated USTS PDOX mouse models on day 14. Arrows show the margin of the tumors. (B) Bar graphs indicate relative tumor volume of each group on day 14. Scale bars: 10 mm. 6 mice were in each group. *p=0.05; **p=0.01; ***p=0.001. Error bars: ±SEM. USTS, Undifferentiated/unclassified soft-tissue sarcoma; PDOX, patient-derived orthotopic xenograft; o-rMETase, oral recombinant methioninase; CL, cycloleucine; DOX, doxorubicin; DAC, decitabine; SEM, standard error of the mean.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    H&E staining. (A, A’) Control. (B, B’) CL alone. (C, C’) o-rMETase alone. (D, D’) DOX alone. (E, E’) CL+DAC. (F, F’) o-rMETase+CL+DAC. Scale bars: 100 μm. o-rMETase, oral recombinant methioninase; DOX, doxorubicin; CL, cycloleucine; DAC, decitabine.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Mouse body-weight. *p=0.05; **p=0.01; ***p=0.001. Error bars: ±SEM. o-rMETase, oral recombinant methioninase; CL, cycloleucine; DOX, doxorubicin; DAC, decitabine; SEM, standard error of the mean.

PreviousNext
Back to top

In this issue

Cancer Genomics - Proteomics: 18 (2)
Cancer Genomics & Proteomics
Vol. 18, Issue 2
March-April 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cancer Genomics & Proteomics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer
(Your Name) has sent you a message from Cancer Genomics & Proteomics
(Your Name) thought you would like to see the Cancer Genomics & Proteomics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
4 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer
TAKASHI HIGUCHI, QINGHONG HAN, NORIHIKO SUGISAWA, JUN YAMAMOTO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, MICHAEL BOUVET, SHREE RAM SINGH, HIROYUKI TSUCHIYA, ROBERT M. HOFFMAN
Cancer Genomics & Proteomics Mar 2021, 18 (2) 113-120; DOI: 10.21873/cgp.20246

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer
TAKASHI HIGUCHI, QINGHONG HAN, NORIHIKO SUGISAWA, JUN YAMAMOTO, NORIO YAMAMOTO, KATSUHIRO HAYASHI, HIROAKI KIMURA, SHINJI MIWA, KENTARO IGARASHI, MICHAEL BOUVET, SHREE RAM SINGH, HIROYUKI TSUCHIYA, ROBERT M. HOFFMAN
Cancer Genomics & Proteomics Mar 2021, 18 (2) 113-120; DOI: 10.21873/cgp.20246
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Comparison of Open-access Databases for Clinical Variant Interpretation in Cancer: A Case Study of MDS/AML
  • Rare KMT2A-ELL and Novel ZNF56-KMT2A Fusion Genes in Pediatric T-cell Acute Lymphoblastic Leukemia
Show more Articles

Similar Articles

Keywords

  • Cancer
  • methionine addiction
  • methionine restriction
  • methionine-methylation-axis blockade
  • decitabine
  • cycloleucine
  • MAT2A
  • soft-tissue sarcoma
  • PDOX
Cancer & Genome Proteomics

© 2021 Cancer Genomics & Proteomics

Powered by HighWire